Goldline Pharmaceutical IPO Subscribed 98.88x; Retail Surges to 137.45x
Goldline Pharmaceutical Limited's ₹8.35 crore SME IPO concluded with a total subscription of 98.88 times, driven by strong retail interest at 137.45x and NII demand with bHNI at 159.41x and sHNI at 116.75x. The pure fresh issue, open from May 12–14, 2026, is set to list on May 19, 2026, with proceeds earmarked for debt repayment and general corporate purposes. The company reported PAT margin expansion from 1.31% in FY2023 to 10.09% in FY2025, with revenue growing to ₹28.06 crore in FY2025.
*this image is generated using AI for illustrative purposes only.
Goldline Pharmaceutical Limited's ₹8.35 crore SME initial public offering (IPO) has concluded with a total subscription of 98.88 times, reflecting strong investor appetite across all categories. The issue, which opened on May 12, 2026, and closed on May 14, 2026, saw exceptional demand from retail investors and Non-Institutional Investors (NII). The company markets pharmaceutical products under its proprietary 'Goldline' brand across five distinct segments, operating entirely on an asset-light, third-party contract manufacturing model with 15 contract manufacturers and 8 distributors.
Subscription Status
The IPO attracted robust demand across investor categories, with retail and NII segments driving the overall subscription numbers significantly higher. The updated figures reflect a marked surge from earlier subscription levels, with the retail category leading at 137.45 times.
| Category | Subscription Status |
|---|---|
| Qualified Institutional Buyers (QIB) | 1.31x |
| Non-Institutional Buyers (sHNI) | 116.75x |
| Non-Institutional Buyers (bHNI) | 159.41x |
| Retail | 137.45x |
| Employees | 0x |
| Total Subscribed | 98.88x |
IPO Structure and Key Dates
The offering was a pure fresh issue with no Offer for Sale (OFS) component. The net proceeds from the issue are intended for repayment of outstanding borrowings — including unsecured loans, term loans, and working capital facilities — with a portion allocated to general corporate purposes capped at the lower of 15% of gross proceeds or ₹1,000.00 lakhs.
| Parameter | Details |
|---|---|
| Issue Type | Fresh Issue |
| Fresh Issue Size | ₹8.35 Crore |
| Offer for Sale (OFS) | Nil |
| Total Issue Size | ₹8.35 Crore |
| IPO Opening Date | 12-May-2026 |
| IPO Closing Date | 14-May-2026 |
| Allotment Date | 15-May-2026 |
| Listing Date | 19-May-2026 |
Financial Performance
The company has reported consistent revenue growth over the reviewed periods. Revenue from operations grew from ₹19.85 crore in FY2023 to ₹23.57 crore in FY2024 and further to ₹28.06 crore in FY2025. For the nine months ended December 31, 2025 (Q3 FY2026), revenue stood at ₹21.41 crore.
| Metric | FY2023 | FY2024 | FY2025 | Q3 FY2026 (9M) |
|---|---|---|---|---|
| Revenue from Operations (₹ Cr) | 19.85 | 23.57 | 28.06 | 21.41 |
| PAT (₹ Cr) | 0.26 | 1.80 | 2.83 | 2.22 |
| PAT Margin (%) | 1.31% | 7.64% | 10.09% | 10.37% |
Profitability improved significantly over the period, with PAT margin expanding from 1.31% in FY2023 to 10.09% in FY2025. Total equity grew from ₹5.89 crore in FY2023 to ₹12.36 crore as of Q3 FY2026, while the debt-to-equity ratio declined from 2.29x to 1.22x over the same period.
Key Risk Factors
Investors should note material risks including third-party manufacturer dependence, concentrated distribution through only 8 distributors, and related-party revenue dependency where promoter group entities contributed 22.04% of revenue. Geographic concentration is also high, with Maharashtra and Madhya Pradesh accounting for over 70% of revenue. Outstanding litigation includes ₹271.23 lakhs in direct tax matters and ₹63.70 lakhs in indirect tax matters.
Given Goldline Pharmaceutical's heavy reliance on only 8 distributors and 15 contract manufacturers, how might the company plan to diversify its supply chain and distribution network to sustain post-IPO growth?
With IPO proceeds primarily earmarked for debt repayment rather than business expansion, what organic or inorganic growth strategies could Goldline pursue to justify its strong investor valuation after listing?
How might Goldline Pharmaceutical's geographic concentration in Maharashtra and Madhya Pradesh limit its ability to scale nationally, and what timeline could investors expect for meaningful geographic diversification?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
